Kazia KZIA 深 滬
等待開盤 11-26 09:30:00 美东时间
12.79
+4.340
+51.36%
華盛通- 最 高14.42
- 今 開8.29
- 成交量 143.80万股
- 最 低 8.1122
- 昨 收 8.45
- 總市值 2070.45万
- 52周最高 22.60
- 市盈率 靜 --
- 換手率 88.83%
- 52周最低 2.90
- 委 比 1.01%
- 總股本 161.88万
- 歷史最高 744.50
- 量 比 0.21
- 振 幅 74.65%
- 歷史最低 3.005
- 每 手 1
- 風險率 4.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Market-Moving News for November 19th
LOW: 6% | Lowe's shares are trading higher despite mixed Q3 financial results. The company raised FY25 sales guidance. PLUG: -22% | Plug Power shares are trading lower after the company announced a $375
11-19 20:21
What Sparked Kazia Therapeutics' Over 51% After-Hours Surge?
Kazia Therapeutics jumped 51.74% in after-hours trading Tuesday after reporting a rare immune-complete response in a patient.
11-19 16:52
Kazia Therapeutics shares are trading higher after the company reported an initial immune-complete response in a stage IV triple-negative breast cancer patient treated under an FDA-authorized expanded access protocol combining paxalisib with pembrolizumab and chemotherapy.
Kazia Therapeutics shares are trading higher after the company reported an init...
11-19 05:19
Kazia Therapeutics Delays 20-F Filing
Kazia Therapeutics ( ($KZIA) ) has released a notification of late filing. Kazi...
11-01 06:17
Kazia Therapeutics Intends To Request And Hold Follow-Up Type C Meeting With FDA To Discuss OS Findings In Newly Diagnosed Glioblastoma Patients Treated With Paxalisib
Kazia Therapeutics Limited ("Kazia" or the "Company") today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug Administration (FDA) to discuss overall survival (OS)
10-27 19:20
美股机会日报 | 9月非农数据悬了？今晚或将无法按计划发布；“木头姐”本周持续加仓阿里、百度
美国政府停摆！9月非农数据悬了？今晚或将无法按计划发布；看好中国科技股AI叙事，“木头姐”本周持续加仓阿里、百度；英伟达对阿联酋芯片出口交易陷入停滞>>
10-03 19:07
美股大行评级 | 潜在涨幅216.96%！Kazia Therapeutics获Maxim Group升目标价至20美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Kazia Therapeutics"买入"评级，目标价从15美元升至20美元；Baird：维持Taysha Gene Therapies"跑赢大市"评级，目标价从7美元升至12美元
10-03 14:32
Kazia Therapeutics Announces Its Participation In A Fully Funded Australian Medical Research Future Fund Project Titled "Sequential & Temporal Therapeutic Agility For The Treatment Of Diffuse Midline Glioma"
Kazia Therapeutics Limited (NASDAQ:KZIA), a clinical-stage biotechnology company developing innovative therapies for brain cancers, today announced its participation in a fully funded Australian Medical Research Future Fund (MRFF) project titled "Sequential & Temporal Therapeutic Agility for the Treatment of Diff
10-01 21:23
Kazia Therapeutics' Paxalisib Shows Complete Disruption Of Metastatic Cell Clusters In Stage IV HER2-Positive Breast Cancer Study
Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by Professor Sudha Rao at QIMR Berghofer.In this ex vivo
09-11 20:05
KANZHUN LIMITED Announces Upsizing and Extension of Share Repurchase Program
KANZHUN LIMITED (BOSS Zhipin) announced the upgrade and extension of its share repurchase program, increasing the authorized repurchase amount from US$150 million to US$250 million and extending the program period to August 28, 2026.
08-20 11:15
